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Abstract

Iliotibial band syndrome is a highly prevalent and painful condition characterized by
anterolateral knee pain from an inflamed iliotibial band, with the current standard of care being
physical therapy. However, we lack sufficient adjunct treatment options for patients with
refractory iliotibial band syndrome who fail physical therapy. This study will evaluate the
efficacy and safety of using botulinum toxin type A injections into the tensor fasciae latae
as an adjunct therapy for patients with refractory iliotibial band syndrome. With all
patients receiving the same physical therapy treatment, we randomized patients to the control
group of saline injection and to the treatment group of botulinum toxin type A injection.
Successful use of botulinum injections will lead to significant improvement in pain and function
in patients with refractory iliotibial band syndrome and open the door for its use in other muscle
imbalance syndromes.

v

Chapter 1 – Introduction

Background

Incidence and Prevalence
Iliotibial band syndrome (ITBS) is a painful and aggravating condition commonly found
in physically active individuals. ITBS is a syndrome of overuse and is highly prevalent amongst
athletes and military personnel1-3. ITBS is considered to be the most common overuse injury of
the lateral knee with incidence ranging between 2 and 12%, and higher rates noted in active
individuals such as runners, cyclists, soccer players, and military recruits,4-6. Among cyclists, the
prevalence of ITBS has been reported between 15-24%7. In a study on female college athletes,
including field hockey, soccer, and basketball players, Devan et al. (2004) demonstrated ITBS to
be the most common overuse injury of the lower extremity8. ITBS has also been noted to be a
common cause of lateral knee pain in rowers, hockey players, triathlon runners, and skiers8-10.

Anatomy
The iliotibial band (IT band) is a fibrous sheath that runs vertically from the iliac crest,
along the lateral aspect of the thigh, to the lateral proximal tibia. It functions as both a tendon,
connecting bone to bone, and a ligament, connecting muscle to bone, thereby connecting and
stabilizing a multitude of vital structures in the proximal leg. The IT band is a fibrous
reinforcement of the tensor fasciae latae (TFL) and originates from the external lip of the iliac
crest on the iliac tubercle. Proximally, the IT band attaches to the TFL gluteus maximus, gluteus
minimus, and vastus lateralis and runs across the greater trochantic bursa. Distally, the IT band

1

connects to lateral femoral epicondyle, quadriceps-patella-patellar tendon complex, and the
biceps femoris muscle tendon-fibula complex. The IT band attaches to the lateral femoral
epicondlye via the patellar retinaculum and epicondylo-patellar ligament. The final insertion
point of the IT band is at Gerdy’s tubercle on the anterolateral tibia2,3,11.
One of the predominant muscles the IT band emerges from is the TFL. The TFL is a
fusiform muscle that originates from the anterior superior iliac spine and the anterior iliac crest.
It is enclosed between two layers of the fasciae lata and, in combination with the gluteus
maximus, merges into the iliotibial band, serving as its attachment proximally. The TFL is an
accessory muscle with its main role being in medial hip rotation and hip abduction, while also
contributing to stability of the knee during flexion and extension1,5,11.

Biomechanics
The purpose of the IT band is not only to contribute to lateral knee stabilization, but also
help coordinate movements of its associated muscles to abduct, extend, and laterally rotate the
hip. In active flexion of the knee, the IT band sits posteriorly to the lateral femoral epicondyle
and assists in knee flexion. In full extension, the IT band moves anterior to the lateral femoral
epicondyle and acts as an active knee extensor. It is this motion of the IT band gliding over the
lateral femoral epicondyle with knee flexion and extension that is the proposed mechanism for IT
band associated knee pain1,2,4,12.
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Pathogenesis
ITBS occurs from overuse and is not considered a traumatic injury. It is characterized by
anterolateral knee pain associated with the distal IT band. However, the exact pathogenesis of
this pain is still is unknown. As we know this is a syndrome of overuse, it is safe to assume the
etiology of the pain is associated with increased movment of the IT band and its associated distal
anatomy. Originally, it was thought to be a direct tendonitis due to friction irritation of the IT
band gliding over the lateral femoral epicondlye, and was therefor perviously termed
“iliotibialband friction syndrome”13. More recent investigation has realitivly disproved this
theory, demonstrating that the IT band is stongly teathered to the lateral femoral epicondlye, and
does not demonstrate sufficient movment to cause friction and inflamed distal ITB14.
One of the more recent predominant theories, was that of an IT band bursitis of the
lateral femoral epicondyle bursa. This theory suggests that the increased rubbing of the IT band
over the lateral femoral epicondyle bursa causes inflammation of the bursa and therefor pain5.
However, flaws have also been associated with this theory. Recent cadaver, MRI, and ultrasound
studies have illustrated that there is no directly associated bursa deep to the IT band at the lateral
femoral epicondlye14,15. The most recent data suggest that the anteriolateral knee pain may be
associated with vascular and innervated adipose tissue deep to the IT band, or compression at the
lateral synovial recess14.
While the exact pathogenesis of IT band syndrome is still unclear, we do know that the
pathogenesis results from overuse and is associated with decreased IT band flexibility and
signature anteriolateral knee pain. A reduction in IT band length and increase in recruitment of
accessory muscles, such as the TFL, has been noted in patiets with IT band syndrome and is
theorized to contribute to the pathogenesis of this syndrome1,4,5. From the current data, it is
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reasonable to work off the hypothesis that IT band syndrome results from increased knee
extension and flexion resulting in a reduction in length of the IT band and irritation to the
anteriolateral knee. Risk factors for developing ITBS include intense cross training, distance
running, cycling, decreased ITB length, and weakness in the muscles of the knee extensors,
flexors, and hip abductors4,11,12.

Diagnosis
Patient history and physical exams are often all that are needed to make the diagnosis of
ITBS. Characteristic anterolateral knee pain localized between the lateral femoral epicondyle and
Gerdy’s tubercle is highly indicative for ITBS. This pain is usually brought on by repetitive
extension and flexion exercises of the knee. Three physical exam maneuvers are commonly
employed to diagnose ITBS; the Noble, the modified Ober, and Thomas test. These physical
exam maneuvers, coupled with a fitting patient history, are highly indicative and oftentimes
diagnostic for ITBS2,3,11,12.
In the Noble test the patient lays supine and the provider flexes and extends the knee
several times from 0-90° while applying pressure to the lateral epicondyle of the femur. Pain or
crepitus is considered a positive Noble’s sign, which is indicative for an irritatted distal IT band.
For the modified Ober test, the patient lies on their unaffected side with their unaffected leg
flexed at the hip and knee. The examiner places one hand on the superior hip to stabilize the
pelvis and the uses the other to flex the knee to 90° while keep the thigh at 0°. If the thigh fails to
fall more than 10° from neutral, it is considered a positive modified Ober test, and in indicative
of IT band and TFL tightness16. Finally, the Thomas test is used to measure the general
flexibility of hip flexors including iliopsoas muscle group, the rectus femorus, gracilis, and TFL.
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In the Thomas test, the patient lies supine and the patient flexes both of their hips and knees,
pulling the legs as far into the torso as possible. The patient then releases and extends the
affected leg; the test is considered positive if the patient’s posterior thigh cannot reach the table
and indicated overall hip flexor tightness4.
Imaging is not needed to diagnose ITBS but is often employed to rule out other knee
pathologies such as arthritis, joint space narrowing, patellar tracking abnormalities, and fractures.
Plain film X-rays will read as normal or benign in patients with ITBS2,3,11. MRI can be useful in
patients with chronic ITBS, as it can demonstrate inflammation and thickening of the IT band
with possible associated fluid buildup over the lateral epicondyle17. However, fluid build up over
the lateral epicondyle has been demonstrated to be non-specific and non-diagnostic to ITBS15.
MRI is also useful in chronic ITBS patients as it helps rule out other knee pathologies as a source
of the patient’s pain, such as tendon and meniscal tears, cartilage degeneration, and cysts.

Current Treatment Options
The current standard of care for ITBS is conservative treatment that consists of rest for
athletic activities with gradual return to activity as tolerated. This activity restriction is
commonly coupled with physical therapy and NSAID use. Physical therapy for ITBS is generally
focused on hip abductor and knee extensor strengthening, and ITB stretching and lengthening11.
Although there is a wide array of specific treatment plans for acute ITBS, the most effective
treatment regimens all involve a combination of rest, ice, physical therapy, NSAIDs2,3. For those
who fail traditional conservative treatment of rest and physical therapy, the next steps in ITBS
management are corticosteroid injection for symptom relief and diagnosis, and possible surgical
release of the IT band. Surgery is considered a final line of therapy for those with refractory or
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chronic ITBS, but is not always a viable option for patients as it comes with its own set of
increased risks and cost3,18.

Statement of the Problem
While rest and physical therapy have been demonstrated to be very effective treatment
options for acute ITBS, few good treatment options exist for those who fail physical therapy. The
few alternate therapies available such as steroid injections or surgical release, come which come
with their own unique set of risks and expenses. This leaves a gap in care for those patients who
continue to have chronic pain and therefore demonstrates a need for new therapeutic options. In
particular, athletes and active young adults are at higher risk for developing chronic ITBS, as
their lifestyle is not conducive to standard conservative treatment guidelines. We are in need of
new adjunct therapies for these patients with refractory pain, who without better adjunct
treatment options, will continue to experience pain or opt for surgical intervention that may carry
more risks than benefits.

Goals and Objectives
The purpose of our study is to investigate alternative adjunct therapies for anterolateral
knee pain associated with ITBS. Our proposed intervention of non-surgical release of the tensor
fasciae latae via botulinum toxin type A (BT) injection coupled with standard physical therapy
will aid in the lengthening of the IT band and hopefully improve therapeutic outcomes. We will
be specifically looking at self-reported knee pain improvement measured with the Anterior Knee
Pain Scale (AKPS) as our primary outcome, as well as functional improvement and IT band
length as secondary outcomes. Information gained from this study will lead to new insight into
treatment options for musculoskeletal pain and adjunct treatments for ITBS and other muscle
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imbalance syndromes. Successful use of BT injections as an adjunct treatment for ITBS will
improve overall pain and function of patients, reduce need for surgical intervention, and reduce
the prevalence of chronic ITBS. In addition, successful treatment of ITBS with BT will open the
door for the use of BT in other musculoskeletal pain syndromes.

Hypothesis
In adults with chronic ITBS, adjunct therapy of a one time .75 units BT in 4mL saline
injection into the TFL, coupled with physical therapy, will have a significant reduction in
anterolateral knee pain at 6 months, measured with the Anterior Knee Pain Scale, when
compared to placebo group, who will receive one 4mL injection of saline into the TFL and
physical therapy.

Definitions
Adults: Patients ages 18-55.
Chronic ITBS: Iliotibial band syndrome for greater than 6 months, with at least one attempt of
conservative standard of care physical therapy for greater than two months.
Treatment Group: Patients randomized to receive a one-time .75units of BT in 4mL saline
injection into the TFL coupled with standard of care physical therapy.
Placebo Group: Patients randomized to receive a one-time 4mL injection of saline into the TFL
coupled with standard of care physical therapy.
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Anterior Knee Pain Scale (AKPS): assesses subjective symptoms as well as functional
limitations surrounding knee pain; it is a well-validated 13 question self-assessment focused on
anterior knee pain with a scoring scale of 0-100, 0 being no symptoms19.
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Chapter 2 – Review of the Literature

Introduction
A comprehensive review of the literature was conducted utilizing PubMed, Cochrane
Library, Emabse, Scopus, Clinicaltrials.gov, and Ovid Medline. The controlled vocabulary
terms searched for were “iliotibial band,” “iliotibial band pain syndrome,” “botulinum toxin,”
and “anterolateral knee pain.” For a wider look and comprehensive review, the key words
“Botox,” “Dysport,” “knee pain,” “IT band,” “tensor fasciae latae,” “runner’s knee,”
“patellofemoral overload syndrome,” and “iliotibial band friction syndrome” were also searched
for. The results of this extensive search of the literature further enhance the need for this study
while also illustrating the basis for this study’s design.

Review of Empirical Studies About the Relationship Being Studied

Iliotibial Band Syndrome
Iliotibial band syndrome is thought to be a syndrome of overuse. It involves weakened
hip flexor muscles and an overactive tensor fasciae latae, with repeated movements leading to
inflammation and pain of the distal iliotibial band1-3. In a case series study by Fredericson et al.
(2000) the authors compared the hip abductor torque of 24 runners with ITBS to 30 control
runners. At baseline, there was a statistically significant difference in hip abductor torque
between the control and ITBS group (p < 0.05). The ITBS group then completed 6 weeks of
physical therapy focused on hip abductor strengthening, at the end of which females
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demonstrated a 34.9% increase in hip abductor torque and males a 51.4% increase in hip
abductor torque. 22 out of 24 participants with ITBS were pain free after 6 weeks and were able
to return to athletics4. This study supports the theory that ITBS is associated with weak abductor
muscles, and demonstrates hip abductor strengthening to be a curtail component in treatment.
In an observational cross-sectional study by Baker et al. (2018), 15 injured runners with
iliotibial band syndrome were compared with 15 control runners to examine the frontal knee and
hip kinematics in patients with iliotibial band syndrome. Data was collected on a 30-minute run
via a three-dimensional, high-speed camera synchronized with wireless surface
electromyography. They demonstrated that runners with iliotibial band syndrome had increased
knee adduction and valgus alignment (P = .002, control = -1.48°, injured = 3.74°) and increased
tensor fasciae latae muscle activation (P = .017, control = 7% maximal contraction, injured =
11% maximal contraction)5. This study offers support to the theory that ITBS is due in part to
weakened hip muscles and overcompensation of the tensor fasciae latae. Therefore, this
biomechanical theory of ITBS also offers rationale to the hypothesis suggested. The hypothesis
that inhibition of the overcompensating tensor fasciae latae, through BT injection, could optimize
physical therapy focusing on hip abductor strengthening and IT band stretching.

Botulinum Toxin in Musculoskeletal Disorders
Botulinum toxin works by paralyzing skeletal muscle and has recently been used
therapeutically in a wide array of musculoskeletal disorders. Its therapeutic paralytic effects have
been demonstrated to be safe and effective in treating disorders such as essential tremor,
Parkinson’s freezing gait, cervical dystonia, and strabismus6-8. Botulinum toxin works by
inhibiting the release of acetylcholine at the neuromuscular junction, causing flaccid paralysis.
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Safety and efficacy of BT injections specifically into the TFL have been investigated in two
studies; one for Parkinson’s freezing gate and another for cerebral palsy. Vastik et al. (2016)
investigated the use of BT injections into the TFL for 10 Parkinson’s freezing gait patients
compared to 10 Parkinson’s patients without freezing gait who did not receive BT injections.
While the results did show that there was a significant decrease in freezing gait symptoms by 3
points (p <0.001), the sample size was very small, and their method of comparison was
questionable. Most importantly, the study showed no adverse effects from the BT injection into
the TFL, and an increase in accessory muscle recruitment9. Brunner et al. (2000) demonstrated
the efficacy of BT injections into the TFL for non-surgical release of the IT band in cerebral
palsy patients with hip malrotation10. Furthermore, BT has become a popular therapeutic option
for patients with cerebral palsy and is widely considered a safe and effective technique in
combating this musculoskeletal disorder11.
In Dunne and Singer (2010) investigated the mechanism and safety of BT uses in the VL
for muscle imbalance syndrome related knee pain. Looking at the long-term effects of BT
injections, this follow up observational study was done to examine the length of denervation of
the vastus lateralis following BT injection. This study investigated a sample of convenience from
subjects previously enrolled in BT for refractory anterior knee pain studies. 9 women and 1 man,
ages 16-25, all of whom had received BT injections into the vastus lateralis for refractory
anterior knee pain in previous clinical trials, were enrolled. All 10 patients reported ongoing
relief of symptoms at the time of the study, but 2 did ultimately undergo surgical intervention for
refractory anterior knee pain. Subjects underwent needle electromyography into the vastus
lateralis to quantify muscle denervation post-injection, measured in motor unit potential (MUP).
All 10 subjects showed a significant reduction in MUP in the injected leg compared with their
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own control non-injected limb, with a mean MUP amplitude reduction of 49% (p=0.0005) and
duration reduction 36% (p=0.0003). The extent of muscle abnormality and reduction in MUP
demonstrated a dose-dependent correlation and a correlation with time sense injection12. While
this study was a small sampled observational study, with a sample of convenience leading to a
contributing sampling bias, it gives us insight into the long-term effects of BT injections into the
vastus lateralis. It encouragingly demonstrates that BT injections are relatively safe and provide
lasting effects on muscle denervation, which could be a promising therapeutic benefit.

Botulinum Toxin and Knee Pain
Botulinum toxin has many uses and is continuing to show promise in the treatment of
many muscle imbalance syndromes7,8,11. Recently researchers have been exploring its use in
specific muscle imbalance syndromes of the knee and thigh, namely with patellofemoral pain
syndrome, patellofemoral overload syndrome, and iliotibial band syndrome. These studies
operate on the theory, that by inhibiting an overactive muscle in the leg with a BT injection, you
will allow for more productive physical therapy and therefore a greater decrease in symptoms.
Overall these studies have had promising results, demonstrating a general improvement in
symptoms with virtually no adverse events or side effects noticed.
Singer et al. (2006) was one of the first to demonstrate the utility of BT injections for
treatment of muscle imbalance syndromes and knee pain. In this study, eight women, ages 18-40,
with a history of chronic anterior knee pain were given BT injections ranging from 300-500 units
into the distal portion of the vastus lateralis, followed by a 12 week at home physical therapy
regiment. The goal of this treatment was to enhance vastus medius recruitment and improve knee
control, which would lead to an improvement in knee pain and function. Results were examined
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through standard CT sequence on the quad, isometric quad strength, and self-reported knee pain
and disability (measured with the Knee Injury and Osteoarthritis Outcome scale (KOOS)). At 12
weeks the patients demonstrated no significant increase in vastus medius cross-sectional area but
did demonstrate a decrease in vastus lateralis cross-sectional area 12.4% (+5%) (p 5 0.05).
Patients also demonstrated an improvement in quadriceps strength as well as knee pain and
function improvement13. While promising, this study, with only eight female subjects, is not
evidence enough to promote the use of BT for anterior knee pain in the general population. In
addition, this study offered no control group, therefore we cannot exclude a placebo effect as a
confounding variable. Due to the lack of control group, improvements in knee pain could
possibly be contributed to physical therapy without any effect from the BT injection; further
studies are needed to investigate this relationship. The KOOS scale was demonstrated to not be
particularly sensitive in the population studied, as most patients were able to remain active
throughout the study. Finally, this study had a relatively short follow-up period of 12 weeks.
Further studies will be needed to examine not only the efficacy, but the safety of using BT
injections long term. In conclusion, this is a promising pilot investigation, but is lacking
sufficient data to demonstrate any true effect.
In 2011 Singer followed up her initial investigational study from 2006 with a double
blind, randomized, placebo-controlled crossover trial study, to examine the efficacy of BT
injections into the vastus lateralis for patellofemoral knee pain. 24 Patients, ages 15-55, with
patellofemoral pain syndrome, clear evidence of vastus lateralis dominance on EMG, and no
other structural knee pathologies or injuries, were enrolled in the study. 14 patients were
randomized to the treatment group and received 500 units BT in 4 mL saline injections into the
vastus lateralis, and the 10 in the control group received 4 mL saline injections into the vastus
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lateralis. The theory behind this treatment plan was that inhibition of the overcompensating VL
would allow for more effective strengthening of the weakened vastus medius, leading to a
correction of the biomechanical muscle imbalance thought to be the cause of these patients’
anterior knee pain. Both cohorts received the same physical therapy and were instructed to
perform exercises at home twice daily. Patients were followed for 24 weeks with pain and
function assessments at 2, 4, 6, 12, and 24 weeks using the Anterior Knee Pain Scale (AKPS). At
the initial endpoint of 12 weeks, significant improvement in knee pain from baseline was noted
in the BT group over the control (p <0.03). Also, at 12 weeks, 5 subjects from the control group
elected crossover and received open-label BT injections. Statistical analysis was not performed
on this group due to small sample size. Long term follow-up at 24 weeks demonstrated that the
initial BT treatment group showed sustained improvement in 11 out of the 14 subjects14. Possible
confounding variables include patient’s adherence to physical therapy, frequency of NSAID use,
extent of previous knee injuries.
Overall, this was a promising follow up study to Singer’s initial investigation into the use
of BT for patellofemoral knee pain that provided an increased level of evidence through the
double-blind placebo-controlled study design. Another promising point in this study was the long
term follow up to 24 weeks, which helps to investigate the use of BT not only as a symptomatic
treatment but also as a curative measured aimed at preventing the need for surgery. Although,
much more extensive follow up with a more detailed data collection and analysis will be needed
to support this claim. Finally, the sample size in this study was too small to make these results
applicable to the general population. Further studies with larger populations and more thorough
follow-up are needed14.
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These promising studies by Singer13,14 demonstrate promise for the short-term use of BT
in treating anterior knee pain caused by muscle imbalance syndromes. For evidence of long-term
safety and efficacy we can look at Silbert et al. (2012). This was a follow-up retrospective study:
46 patients from previous clinical trials and 19 patients from private medical clinics who had
received the same treatment of a one-time injection of BT into the vastus lateralis for
patellofemoral knee pain were surveyed, in an attempt to examine the long-term effects of this
treatment. This study was primarily measuring self-reported symptom relief and if knee surgery
was required post-injection. They found that a single BT treatment led to an initial improvement
in pain and function in 57 out of 65. 44 of those 57 patients who reported initial symptom relief
stated that they continued to have long-term treatment benefits for an average of 34 months (SD
25) post-injection15. This study only reported the mean treatment benefit length for those who
sustained long-term results; they did not expand upon the 8 patients who received no initial
benefit and the 13 patients that only received short-term treatment benefits.
The role of BT in the treatment of knee pain associated with patellofemoral syndrome has
been supported by numerous other studies16-18. Chen et al. (2015) was a prospective case control
study for intervention, where 12 patients with bilateral anterior knee pain associated with
patellofemoral syndrome received BT injections into the VL of their worse knee and used their
non-injected knee as a control. This study demonstrated a significant reduction in anterior knee
pain assessed with the WOMAC self-reported knee pain questionnaire (p<0.05)17. With a small
sample size and patients acting as their own control, this study offers a low level of evidence on
its own, but offers support to the use of BT for anterior knee pain.
While there is increasing evidence for the use of BT injections in the VL for treatment of
knee pain associated with patellofemoral syndrome13-15,19, only one case series study has been
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done to evaluate the safety and efficacy of botulinum toxin type A in the TFL. Stephen et al.
(2016) used ultrasound guided botulinum toxin injection into the TFL followed by physical
therapy in 45 patients classified as having patellofemoral overload syndrome from either ITBS or
superolateral fat pad impingement. Significant improvement in knee pain, measured using the
Anterior Knee Pain Scale, and in IT band length, measured via the modified Ober test was
demonstrated in 39 out of 45 patients. Symptom improvement in this study is suggested to be
due to reduced lateral TFL/ITB tension, leading to increased hip abductor strength via the
inhibition of the TFL. Overall, this study illustrates the safety and possible efficacy of using
botulinum toxin injections into the TFL as an adjunct therapy for anteriolateral knee pain caused
by ITBS. The drawback to this study is that it is designed as a case control and all participants
acted as their own control. Therefore, the level of empirical scientific evidence is low, and
confounding variables and placebo effect cannot be ruled out. Furthermore, this study focused on
the treatment of anterior knee pain categorized as “patellofemoral overload syndrome” caused by
either ITBS or superior lateral fat pad impingement, and was not focused on the treatment of
ITBS anterior lateral knee pain specifically. This study provides evidence that botulinum toxin
could be a viable treatment of ITBS, as it demonstrated a reduction in knee pain and lengthening
of the IT band, but further studies are needed to evaluate this hypothesis20.

Review of Relevant Methodology

Patient Selection
ITBS is a highly prevalent condition frequently seen in orthopedic sports medicine
clinics2. Therefore, orthopedic sports medicine clinics are an optimal place to recruit participants
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for ITBS research. In Fredericson et al. (2000), patients were recruited from an orthopedic
runner’s injury clinic. They were chosen based on history and physical exam with the prominent
symptoms being lateral knee pain, local tenderness over the lateral epicondyle, a positive Noble
compression test, and the absence of any other knee injury such as effusion or tendon injury.
Patients were excluded if they had any history of previous knee trauma, surgery, or other
abnormal knee findings4. The history and physical exam findings used as selection criteria for
this study are quite specific and reliable techniques for isolating patients with ITBS, but they
lacked the use of imaging for more definitive diagnoses.
Baker et al. (2018) recruited patients by either referral from a local running club or
orthopedic clinics, and utilized similar inclusion criteria at Fredericson et al. (2000) for isolating
patients with ITBS for their study. They also relied on the Noble compression test as a key
diagnostic factor for ITBS, and excluded patients if they had signs of any other knee injury other
than ITBS. One inclusion criteria specific to this study was that all their participants had to run at
least 10 miles per week before injury1. While this is a good inclusion criteria when specifically
studying runners, it limits the patient population considerably. Inclusion criteria and recruitment
techniques for the study being proposed will include components of these two studies, including
the recruitment from sports medicine clinics and the utilization of the Noble test as an inclusion
criteria.

Study Design and Intervention
The intervention suggested in this study will be based off of Stephen et al. (2016). Their
study protocol used a .75units ultrasound guided injection of BT in 4mL of saline into the TFL.
The participants were then started on a physical therapy regime, and mean change in knee pain,
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measured with the AKPS, and mean change in ITB length, measured with the modified Ober,
were measured at 6 weeks20. One drawback of this study was the absence of a control group.
Therefore, we will be adapting and expanding upon their study design and incorporating the
study design outlined in Singer et al. (2011). They employed a placebo control, double-blinded
study design where patients were randomized into treatment group and control group. The
treatment group received 500units of BT into their VL and the control group received the
equivalent volume of saline injected into their VL. Primary outcome at 12 weeks analyzed
reduction in knee pain using the AKPS. Treatment crossover was allowed at this point and
patients were followed for 24 weeks14. From the Singer et al. 2011, we will incorporate the
double-blind placebo control methodology, as well as their 24-week end point.
The Noble and Thomas test will not be used as secondary outcome measures, and as
neither have been used in previous studies involving BT injections and therefor would be
difficult to compare to other relevant literature. In addition, and more importantly, the Noble test
is dichotomic and not quantifiable. The test can only be considered positive or negative and has
no way to quantifiably measure improvement. While the Thomas test can demonstrate
quantifiable improvement, it is considered a more general test of hip flexor flexibility and is not
specific to the IT band or TFL1-3.

Data Collection Techniques
The primary outcome of interest is the reduction in mean knee pain measured by the
AKPS. The AKPS is a well-validated assessment tool for self-reported knee pain, and has been
used in many of the studies discussed previously to examine the relationship between BT
injections and knee pain14,15,19,20. Ittenback et al. (2016) conducted a secondary analysis of
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prospective epidemiologic data to determine the validity and reliability of the AKPS. The records
of 414 teenage females were used for analysis of four different methods of AKPS scoring and
analysis. All four scoring formats of the AKPS demonstrated to have a high internal consistency
(αcoef = 0.83 to 0.91) (SE: 0.82 to 3.00), and “moderate to high criterion related validity-as
determined by physician’s diagnosis”: 0.92 (13-item form), 0.90 (6-item form)21.
The modified Ober technique is a physical exam maneuver used to assess tightness of
ITB and TFL. This physical exam maneuver is done by having a patient lay on their side, with
hips in neutral position, knees straight, and with the leg of interest on top. The provider stands
behind the patient, using one hand to stabilize the pelvis and keep the hips in a neutral position,
and the other to abduct and extend the superior leg with knee at 0°, and then slowly allows the
leg to adduct to its resting position. In this position, if the leg cannot fully adduct and remains
above the lower knee the test is considered positive and a sign in ITB/TFL tightness1,20,22. Reese
and Brandy (2003) used an inclinometer to measure the degree of hip adduction or abduction of
the leg in the Ober and modified Ober position in a study of sixty-one subjects. A horizontal leg
was considered to be at 0°, adduction was recorded as a positive number, and abduction was
recorded as a negative number. This study demonstrated the interclass correlation values for the
reliability modified Ober test was 0.91, illustrating the modified Ober test is reliable assessment
of ITB/TFL flexibility22. This method was also used in a study discussed previously by Stephen
et al. (2016) to assess the relationship between BT injections into the TFL and ITB length.

Data Analysis
For calculating effect and sample size we will be using the study framework and results
from Stephen et al. (2016) and Singer et al. (2011) as they are studies of similar populations
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looking for mean change in knee pain using the AKPS as their primary outcome. Stephen et al.
(2016) based their power calculation off changes in AKPS in a similar population studies in
Singer et al. (2011), demonstrating that they needed a sample size of 45 to calculate an 80%
power 95% confidence. To account for drop out 55 patients were recruited, and 45 patients
completed the study. They used paired T-tests were used to compare pre-injection AKPS scores
to endpoint AKPS scores20. In contrast, in Singer et al. (2011) they used unpaired T-tests to
compare changes in AKPS scores between treatment and control group. The study being
proposed will use a combination of the data analysis outlined in Stephen et al. (2016), using
paired T-tests to monitor for changes in AKPS and modified Ober tests within groups, and
Singer et al. (2011), using unpaired T-tests to illustrate mean changes in AKPS and modified
Ober tests between groups. As these two studies are most prominent in the medical literature,
and most similar to our outcome of interest, our study design will incorporate aspects of their
design to allow for consistent data across studies that can be readily comparable.

Safety and Monitoring of Adverse Events
Very few serious adverse effects have been noted in previous studies that used BT
injections into the VL for knee pain. Stephen et al. 2016 noted two mild adverse events: one
patient experienced increased pain after injection, and one patient had an anxiety attack the day
after the injection, which the patient felt could have been related to the injection. The only
adverse event in Singer et al. (2006) was injection site pain and soreness. Singer et al. (2011)
noted injection site bruising and soreness and slight distal thigh asymmetry as an adverse event
in their study. Finally, in Chen et al. (2015), no adverse events were reported. These studies
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demonstrate that the intervention being proposed is relatively safe and low risk; the study design
will reflect the risk level appropriately while being vigilant for any possible complications.

Review of Confounding Variables
There are a few confounding variables, worthy of note, and present in this study
including physical therapy adherence, variability in outcome measures, and demographic
variance. While study design will attempt to control for these and minimize their effects on study
outcome, it is important that they be acknowledged.

Physical Therapy Adherence
It is well known that physical therapy is considered first line standard of care for ITBS,
and in itself generally produces a reduction in patient’s pain level23,24. Therefore, it is safe to
assume that the more adherent a patient is to the physical therapy regime in this study, the more
likely they are to have a reduction in knee pain regardless of intervention status. Results can also
be impacted by the variability in instruction provided by physical therapist, and how much the
physical therapy program must be tailored to patient’s needs. These variables will be controlled
for as best as possible in study design, but it is important to be cognizant of the relationship
between physical therapy and reduction in ITBS symptoms.
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Variability in Outcome Measurements
The primary outcome of interest is the mean reduction in knee pain between the treatment
and the control group measured with the AKPS. The AKPS has been demonstrated to be a valid
measurement tool for self-reported symptoms, and is widely used in the orthopedic community21.
While this assessment tool has demonstrated a high degree of reliability, it is important to note
that it is still a patient self-report of pain and therefore is inherently subjective. The secondary
outcome of interest, mean change in IT band length, measured with the modified Ober test,
demonstrates a slight variability in outcome measurements, as it is a modified physical exam
technique and therefore operator dependent. Although it has been demonstrated to be a reliable
technique to measure ITB/TFL length and has been used as a method of data collection in
previous studies20,22, it must still be acknowledged that this measurement is user dependent and
therefore comes with variability.

Demographic Differences
It has been well documented in epidemiology statistics that women have higher rates of
ITBS than men1,3,25,26. In Day and Gillet (2019) 30 asymptomatic patients (15 male, 15 female)
ran while data were collected via motion-capture system and force platform. Females
demonstrated a statistically significant higher ITB strain rate than in men (p<0.05)25. In an
observational cross-sectional study by Kim et al. (2019), authors measured ITB strain using real
time elastography ultrasound and found an increased IT band strain with genu varum knee
alignment when compared to normal women (4.42 ± 1.42, P = .048) and normal men
(3.50 ± 1.04, P = .005)26. It has been suggested that it is a difference in biomechanics and hip
muscle activation that may account for this prevalence difference between sexes1,4,25,26. This
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demographic difference may contribute to a selection bias and influence data outcomes based
upon the ratio of male to female participants.

Conclusion
The exhaustive search of the medical literature presented demonstrates an ample amount
of evidence in favor of the hypothesis and study design being proposed. Through the research
presented above, we can see that ITBS is often associated with weak hip abductors by over
activation of the TFL, leading to tightness and inflammation of the ITB; which is why hip
strengthening physical therapy and lengthening of the ITB provide symptom relief1,2,4,5. It has
also been demonstrated the BT injections have shown successful outcomes in the treatment of
knee pain when injected into the VL for patellofemoral syndrome13-16 and into the TFL for
superolateral fat pad impingement and ITBS20. The review of the literature supports this study’s
proposed mechanism of action, that temporary paralysis of the TFL will allow for more effective
hip abductor strengthening and ITB lengthening, resulting in a significant reduction in knee pain.
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Chapter 3 – Study Methods

Study Design
The study being proposed will be a double-blinded, placebo-controlled, randomized
control trial, to investigate the use of botulinum toxin type A injection into the tensor fasciae
latae as a viable adjunct treatment for chronic refractory ITBS.

Study Population and Sampling
Patients, ages 18-50, will be recruited from orthopedic sports medicine clinics that have a
history of chronic or refractory ITBS. Patients with ITBS will be selected on history, and
physical exam. X-ray and MRI may be used to rule out any other structural pathology if already
available in a patient's history.
Patients were considered if they met the following inclusion criteria:
1. Symptoms lasting longer than 6 months
2. History of previously failed physical therapy, for at least two months
3. Pain localized to the anterolateral knee
4. Pain worsens with strenuous athletic activity.
Patients were excluded from the study if they met any of the following exclusion criteria:
1. Previous surgery on injured knee
2. Knee instability
3. Current injury to the knee other than to the IT band (ex: patellar subluxation, tendon t
ear, or fracture)
4. Moderate or severe osteoarthritis
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Subject Protection and Confidentiality
Study design will be submitted to Yale’s Institutional Review Board for approval through
the IRES IRB system. Patient consent forms will ensure that patient’s data will not be shared
without their consent. Forms will state that we will not share patient data or information with
outside parties, and all data published or shared will be deidentified. Consent will allow
researchers full access to the patients’ medical records for study research as well as patient
safety. All members of the research and treatment teams will sign confidentiality and HIPPA
agreements.

Recruitment
Patients will be recruited from orthopedic sports medicine and primary care sports
medicine clinics in Connecticut either by provider referral, review of medical record, or patient
request. Recruitment flyers will also be posted at athletic facilities, physical therapy practices,
and orthopedic clinics throughout the greater New Haven area. All patients will undergo a
thorough review of their medical records, as well as history and physical examination by the
study’s lead providers to confirm patients’ eligibility.

Study Variables and Measures
The independent variable, which will be received by the treatment gorup, is the injection
of .75 units of botulinum toxin type A (BT) in 4mL of saline into the TFL. The control group
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will not receive the independent variable and will instead receive a placebo injection of 4mL
saline into their TFL. Both the treatment group and the control group will receive the same
physical therapy instruction.
The main dependent variable, and primary outcome, is mean reduction in pain from
baseline measured via the AKPS at 24 weeks. The AKPS is a self-reported knee pain scale that
provides a more detailed look at knee pain in relation to patient activity and functional level. The
AKPS will be administered at week 0, 1, 2, 4, 8, 12, and 24 to monitor the effects of treatment
overtime. The primary outcome of interest in mean reduction in knee pain, measured with the
AKPS, from week 0 to week 24.
The secondary outcome of interest will be the mean change in IT band length from
baseline. IT band length will be measured using the modified Ober test, where flexibility will be
measured with an inclinometer. The modified Ober test is a physical exam maneuver where the
patient lies on their unaffected side while the provider extends their injured leg with the knee in
extension. The inclinometer is then placed on the lateral epicondyle of the femur. Abduction is
read as a negative number, adduction read as a positive number, with true horizontal reading at
0°. IT band length will be measured at baseline, and at 1, 2, 4, 8, 12, and 24 weeks.

Physical Therapy Regime Received by Both Groups
Physical therapy for both groups will follow standard practice guidelines for ITBS and
will primarily consist of diffuse, lower-extremity stretching focused on the IT band, hamstring,
gastrocnemius, and soleus. In addition, physical therapy will also include strengthening
components focused on the hip abductors and quadriceps. Physical therapy will be conducted
once a week by certified physical therapists at Yale Physical Therapy Centers in New Haven and
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Milford. Physical therapy sites will be trained on study protocol and the specific rehab regiment.
These physical therapists will be instructed to perform the same set of exercises with all patients,
educate the them about at home exercises, and advance the them as appropriate.
Patients will all be given a physical therapy exercise log that outlines the week's
exercises. They will meet with the physical therapist on the first day of each new exercise log
week so the physical therapist can instruct them on proper exercise technique. Every patient will
be given the same set of exercises each week. The exercise difficulty will increase each week. At
any point throughout the study, if the patient cannot tolerate the increase in difficulty or if the
physical therapist recommends not advancing the patient, they will continue to repeat the highest
level of difficulty tolerated until they can progress further, or the study ends.

Blinding of Intervention
To ensure continuity in technique and limit bias, the same provider will perform all
injections. This provider will be the only unblinded member of the research team, and after
administration of injection will not participate in further patient care, data gathering, or data
analysis. The patient, physical therapist, and continuing care provider will be blinded to which
treatment the patient has received.

Assignment of Intervention
Patients will be randomized into two groups of roughly 150 participants, depending upon
recruitment, via computer generator stratification program. These randomized control and
intervention groups will be subsequently stratified based on age, gender, weight, activity level,
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IT band length relative to height, and baseline pain score. Random treatment allocation and
variable stratification will help ensure that the two groups are as uniform and comparable as
possible.

Adherence
The initial intervention, which is the independent variable, is a one-time injection into the
TFL. This is done under direct supervision of research staff and therefore adherence to the
intervention will not be an issue in this study. However, the physical therapy adherence and
activity level compliance need to be monitored. The physical therapists will fill out a patient
adherence form that will include: how many treatment sessions were missed and a qualitative
assessment of patient adherence and progression in physical therapy activities. Patients will
receive a physical therapy log that outlines each day’s physical therapy activities and with a box
to check when completed. The patients will update this log each day to mark their completion of
that day’s activities. At the end of each week’s physical therapy log they will be asked to sign to
attest to their log’s accuracy. This log will be shared with the research staff at each office visit to
track patient’s adherence to physical therapy regiment.

Monitoring of Adverse Events
No significant adverse effects were noted in any previous study of BT injections into the
TFL or the VL. Mild adverse effects that did occur were injection sight pain, redness, and one
anxiety attack. For these mild, but possible, adverse events we will have patients fill out a selfreported questionnaire throughout the study. Questionnaires on adverse events will be performed
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on the day of injection, and at each research visit. Patients will be encouraged to reach out to the
researchers at any point in the study with whatever concern they may have. The only severe
adverse events that are notable are infection or allergic reaction from the injection. Although, we
consider this to be very unlikely and has not been seen as an outcome in any previous studies of
note. For this and any other severe adverse event, we will encourage patients to seek medical
attention promptly, document the adverse event thoroughly, and release them from the study.

Data Collection
The primary outcome of interest is mean reduction in knee pain from baseline. This will
be measured using the AKPS and will be assessed at research office visits at week 0, 1, 2, 4, 8,
12, and 24. The secondary outcome of interest is the mean change in IT band length from
baseline. IT band length will be assessed through the modified Ober test and measured with an
inclinometer at week 0, 1, 2, 4, 8, 12, and 24. Both of these data collection techniques are
outlined in further detail above in “Study Variables and Measurments.” These data points will be
collected at baseline and follow up office visits at Yale Physician’s Building Orthopedic Clinic
by study provider.

Sample Size Calculation
For the given effect size (population means of 15.00 vs. 8.60), standard deviation of 16,
treatment group sizes of 148 and 148, and an alpha of 0.010 for a 2-tailed T-test the power is
0.801. A Bonferoni correction was chosen correcting our alpha to 1% to correct for errors in
sample size calculations and prevent a false positive. For this study we will need a sample size of

36

296 to discern a significant difference between treatment and placebo group analyzed with a 2tailed T-test. To account for an expected 10% attrition rate 330 patients will need to be enrolled.
Sample size calculations are based on results from Singer et al. 2011 and Stephen et al. 2016.

Analysis
Both the primary outcome of interest, reduction in knee pain from baseline, and the
secondary outcome, change in IT band length from baseline, will be treated as continuous
variables. These variables will be compared individually by the students paired T-test, and as a
mean change by group with the student T-test. The random allocation of control and treatment
groups in combination with group stratification based on possible confounding variables will
allow for easily comparable homogenous groups.

Timeline and Resources
The Recruitment Phase is the first phase of the study that will run for one year from
01/01/2021-12/31/2021. The Experimental Phase will overlap with the recruitment phase by six
months and will also last one year from 07/01/2021- 06/31/2022. With the last patients will be
enrolled in the study at the end of 2021, and the study run for 6 months, the latest patients
enrolled will be finished with the study protocol by mid 2022. Data will be collected throughout
the experimental phase. This will leave six months for the final analysis phase, from 07/01/202212/23/2022, where final data collected in the experimental phase will be analyzed and
disseminated.
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The study will be conducted at Yale Orthopedics/Sports Medicine at the Yale Physicians
Building in New Haven, CT. The research team will include four providers. The first provider
will be the only unblinded member of the study. This unblinded member will administer the
injection into the TFL and will not be involved in any other aspect of research after injection
administration. The other three providers will assist with recruitment, perform baseline
assessment and confirm diagnosis of chronic ITBS. They will also conduct the study’s follow-up
visits and perform the modified Ober test to measure IT band length. Physical therapists from
different Yale physical therapy sites throughout the greater New Haven area will be needed to
conduct physical therapy sessions with participants. Finally, a team of five research assistants
will be needed to help with patient recruitment, enrollment, data collection and analysis. Besides
botulinum toxin injections, equipment already available at the sports medicine clinic and
physical therapy offices will be sufficient for study needs.

Ethical Considerations
While this study proposes a relatively safe and non-invasive procedure, there are a few
ethical considerations to be addressed including randomized allotment of treatment and control
groups. Both groups will receive injections, which carry their own risks of infection, injection
site pain, bruising, and swelling. The placebo group will receive an injection without the
possibility of treatment. While the treatment group will receive an off-label use injection. Both
groups carry their own risks and ethical considerations, which will be carefully monitored
throughout the study. Overall the study proposed is a relatively safe procedure with minimal risk
and ethical concerns.
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Chapter 4 – Conclusion

Advantages and Disadvantages

Problem Definition
The problem, as stated, is a lack of treatment options for patients with chronic ITBS who
fail conservative management. This is particularly common in highly active and athletic patients,
not only because ITBS is more prevalent in these populations, but also because these patients
often have a hard time refraining from activity long term. In an overuse injury such as ITBS,
pain is provoked with increased activity. For those who fail traditional rest and physical therapy
techniques their options are either to maintain their activity level and experience pain, undergo
surgical intervention, or forever limit their activity and athletics. The goal of this study was to
propose a new intervention that would allow patients to reduce their pain levels and avoid
surgery, while maintaining their activity level and quality of life.
As athletes and active adults often have the highest rates of ITBS, because of this our
study population will have high rates of athletes and atcive adults than represented in the general
public. This makes the results less applicable to the general population. In addition, as ITBS is a
syndrome of overuse, this population with the highest level of activity will presumably have the
most severe symptoms at baseline. With a higher starting point for symptom severity, it will be
easier to find a statistically significant reduction in symptoms. While this is not likely to cause a
significant problem in data analysis, it is important to keep in mind the applications of this study
in reference to the study population.
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Validity of Methods
The methods outlined in this study represent the most rigorous and detailed approach
possible within practical limits. The study design is a randomized, double-blind, placebo-control
trial, chosen to yield the highest level of empirical results. Treatment group allocation is done
randomly and then stratified based on demographics and possible confounding variables to
ensure the most homogenous groups possible for comparison. Allocating treatment allows for the
intervention effect to be examined more precisely, by reducing allocation and selection bias.
Patients, providers, physical therapists, and researchers were blinded to treatment allocation,
reducing both the placebo effect and experimenter bias.
The primary outcome of interest, mean reduction in anterior knee pain at 6 months, was
measured with the AKPS. The drawback to using the AKPS as a tool in a placebo trial is that
patients not receiving the intervention might believe that they are and therefore experience a
placebo effect reduction in pain. However, patients in the intervention group that might
experience the same phenomena should match this effect. Since the AKPS is solely self-reported
with no additional empiric data, it comes with its own limitations. While the AKPS is inherently
subjective as it is a self-reported pain scale, it has been demonstrated to be a valid measurement
for anterior knee pain. The AKPS is also one of the more popular surveying tools used in
orthopedics, and was used in multiple previous studies, making our results easily comparable to
the relevant medical literature.
The secondary outcome of interest, mean change in ITB length, measured with the
modified Ober test allowed for understanding of the physiology behind ITBS. A correlation
between increased ITB length and reduction of pain suggests a relationship between ITBS knee
pain and ITB length. This however is not enough to demonstrate causation, but in combination
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with the medical literature, supports the theory that ITBS associated knee pain is due in part to a
short and tight ITB. Furthermore, this correlation suggests a mechanism for why BT injections
into the TFL could reduce ITBS related knee pain. By paralyzing the TFL the ITB is allowed to
relax and lengthen, leading to a reduction of inflammation and pain.
In terms of analyzing our primary and secondary outcome data, both the paired T-test and
unpaired T-test were utilized. The paired T-test allowed for comparison of individual data,
comparing each participant’s baseline to their endpoint to determine if they had experienced a
significant change in knee pain or IT band length. This helped us further explore the relationship
between ITB length and knee pain in patients with chronic ITBS. In addition, it also helped us
look at individual responses to either the intervention or control and break down results based on
demographic and confounding variables for a more in-depth statistical analysis.
The unpaired T-test was utilized to understand the mean change difference in outcome
variables between groups. The mean change in knee pain and ITB length was calculated for each
group and compared with the unpaired T-test to determine if there was a statistically significant
difference in outcome between the two groups. The unpaired T-test comparing the mean
reduction in knee pain between the control and treatment groups was considered the primary
outcome of interest in this study. Therefore, this test determines the validity of the study’s
hypothesis, and whether we can view BT injections into the TFL as a viable adjunct treatment
for chronic ITBS.
Both the paired and unpaired T-tests are highly validated techniques used to determine if
a difference between two groups is significant. The only drawback in their utilization is the limit
in their ability, they cannot track changes over time, analyze time to an event, or determine the
number needed to treat. These outcomes were not addressed in our analysis as they were not a
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part of this study’s hypothesis and not accounted for is the study design. For our purposes the Ttests are sufficient to determine the validity of our hypothesis.

Generalizability of Study Results
The results of this study hold great significance for patients suffering with chronic ITBS
as it offers a viable adjunct treatment for their pain, avoid surgical intervention, and return to
their level of activity/athletics without issue. The patient population in this study was 18-55 with
chronic ITBS. As ITBS is a syndrome of overuse our study population will primarily consist of
athletes and active adults by default. Therefore, the results of this study are easily applied to
populations such as college athletes, military recruits, and generally active or athletics adults
with chronic ITBS. As the study population was composed of chronic ITBS patients, and
because physical therapy is known to be a successful initial treatment for ITBS, the results of this
study are not necessarily applicable to all patients with ITBS. In addition, this study did not look
at populations outside the 18-55 age range, populations with additional knee complications, or
sedentary populations with ITBS. Therefore, the results of this study cannot be applied directly
to these populations but can serve as a guide for future studies and treatment interventions in
these groups.
Although the results of this study may not be applicable to all patients with ITBS, it does
have further applications outside of the ITBS patient populations. Research in other muscular
imbalance syndromes with similar pathophysiology to ITBS, in particular patella femoral
syndrome, could benefit from the results of this study. While the results of this study may not be
specifically generalizable to outside of ITBS, they are relevant to a wide variety of similar
conditions. In addition, the results of this study give us more information about the safety and
efficacy of BT treatment and may open the door for its use in other conditions.
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Clinical Significance
Successful use of BT to treat ITBS would leave a positive impact on clinical practice and
ITBS treatment. Successful implementation of this strategy could reduce the number of patients
opting for surgical intervention. Surgery comes with a greater risk of complications and a greater
expense to the patient. Avoiding surgery would allow for an overall reduction in both risk and
cost for the patient. BT treatment being less expensive than surgery would also offer a treatment
option for patients with chronic ITBS that could not afford surgery, creating a treatment option
that is more accessible to a wider population. With the possibility of more patients with chronic
ITBS opting for BT intervention due to its minimal risk and cost, we could see a greater
reduction in prevalence of chronic ITBS.
BT therapy for ITBS not only allows for a viable alternative treatment for ITBS itself but
creates an avenue for new therapies and greater understanding of various pathologies. Successful
use of BT here would provide a basis for BT therapy in other disorders related to the IT band,
including greater trochantic bursitis, and to other muscle imbalance disorders. In addition to
promising therapeutic discoveries, this study will also afford researchers a greater understanding
of the pathology behind ITBS. As the IT band is connected in some way to almost all the major
components of the lower limb, a deeper understanding of its biomechanics is crucial to a wide
variety of pathologies. By inhibiting one of the IT band’s major muscle attachments we can gain
a greater understanding of its biomechanics that could lead to more affective physical therapy
and other treatments.
Finally, BT treatment for ITBS is a less risky and medically intensive procedure,
allowing for mid-level providers such as PAs and NPs to perform this without needing physician
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supervision. Many PAs across the country, and in a wide variety of medical specialties already
treat and care for patients with ITBS. This treatment strategy, if proven a viable adjunct therapy
for ITBS, could commonly be performed in outpatient orthopedic, sports medicine, and even
primary care clinics. BT treatment will give patients and providers a greater array of noninvasive
treatment options for refractory and chronic ITBS, leading to more autonomous treatment
options for ITBS by PAs.
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APPENDIX A: Sample HIC
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL

Study Title: Tensor Fasciae Latae Botulinum Injections as an Adjunct Treatment for Iliotibial
Band Syndrome
Principal Investigator: Michael Medvecky, MD; J. Morgan Jones, PA-SII
Funding Source: Yale University School of Medicine: Physician Associate Program

Invitation to Participate and Description of Study
You have been invited to participate in a study to test the effects of botulinum toxin
(Botox) injections into the tensor fasciae latae on chronic iliotibial band syndrome related knee
pain. You have been asked to participate because you have been diagnosed with iliotibial band
syndrome, have previously failed conservative therapy, and have had symptoms for more than
six months. Approximately 300 patients will participate in this study.
Iliotibial band syndrome is a common injury of overuse seen in athletes and active
populations. It is categorized by inflammation of the iliotibial band causing irritation and knee
pain. The standard of care for this condition is considered to be conservative management of rest
and physical therapy. However, many patients fail conservative therapy and develop chronic
symptoms. For these patients the next level of management is considered to be steroid therapy
and/or surgical release of the iliotibial band. Both of these second line therapies come with their
own increased set of risks.
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This study proposes an alternate adjunct therapy for patients with chronic iliotibial band
syndrome with the hopes of symptom reduction and to prevent the need to escalate to
steroid/surgical therapies. Thus, producing a viable alternative therapy to improve patient’s
symptoms and quality of life while allowing them to avoid more invasive and expensive
therapeutic options.
In order to decide if you wish to participate in this study, it is important to understand the
study’s procedure and all risks associated with it. This form provides information about study
protocol as well as risk and benefits. A research team member will review this form with you and
make sure you understand what will be expected of you, outline the procedure, explain all the
risks involved, and answer any questions you may have. Once you understand the study you will
be asked if you wish to participate, if so you will be asked to sign this form.
Description of Procedures
This study's purpose is to investigate the efficacy of using botulinum toxin injections into
the tensor fasciae latae in combination with physical therapy to improve iliotibial band syndrome
associated knee pain. Roughly 330 patients will be enrolled and then randomized into either the
treatment group or the control group. Randomization will be done via computer generator and
will not be based on any personal data. Neither the patient nor the research team will know what
treatment group you have been assigned to. Patients randomized to the treatment group will
receive a one-time injection of .75units of botulinum toxin into their tensor fasciae latae. Patients
randomized to the placebo group will receive a one-time injection of 4mL of saline into their
tensor fasciae latae. Both groups will be given the same physical therapy regime. The length of
the study from injection to conclusion is 24 weeks.
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Participants will be expected to participate in eight total office visits. At each office visit
we will ask participants to fill out the Anterior Knee Pain Scale (AKPS) to monitor their
symptoms severity. In addition at every visit the research provider will perform a physical exam
maneuver called the modified ober test, where the participant lays on their side and the flexibility
of their IT band is measured with an inclinometer. An inclinometer is a noninvasive instrument
placed against the leg of the patient that reads the angle at which the leg is resting.
Visit 1- Pre-Study: Study eligibility evaluation and consent, AKPS and Modified Ober Test.
Visit 2- Week 0: Tensor fasciae latae injection, AKPS and Modified Ober Test.
Visit 3- Week 1: Check up with research staff, AKPS and Modified Ober Test.
Visit 4- Week 2: Check up with research staff, AKPS and Modified Ober Test.
Visit 5- Week 4: Check up with research staff, AKPS and Modified Ober Test.
Visit 6- Week 8: Check up with research staff, AKPS and Modified Ober Test.
Visit 7- Week 12: Check up with research staff, AKPS and Modified Ober Test.
Visit 8- Week 24: Study Conclusion. Check up with research staff, AKPS and Modified Ober
Test.
In addition to office visits patients will be required to attend physical therapy once a
week, and conduct at home exercises once a day. Patients will keep track of their at home
physical therapy through a physical therapy log that will be reviewed by the research team at
appointments to track therapy progress and adherence. Aside from physical therapy patients are
encouraged to rest, and advance to more strenuous activity as advised by the physical therapist.
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All study participants will be kept informed of any major study developments as they
occur. If for any reason we find that one treatment is superior to the other during the course of
the study, we will terminate the study and offer the superior treatment to all participants.
Participants are encouraged to reach out to research staff if they have questions, concerns, or
issues at any point in the trial. Patients will be able to withdraw from the study at any point with
no penalty or consequences.
This study and all relevant information will be listed on clinicaltrials.gov in accordance
with national law. You are welcome to access information on this study at this site at any time.

Risks and Inconveniences
We do not anticipate any significant risks or adverse events while participating in this
study. The most likely adverse event will be injection site pain or bruising, this will be monitored
for and the study will provide ice packs and NSAIDs on day of injection at patients request on
injection day to offset this inconvenience. An unlikely but possible risk of this procedure in
injection site infection, injections will be done with proper sterile technique to minimize this risk.
Theoretical side effects include allergic reaction, muscle atrophy, and tendon rupture. These are
all highly unlikely and are only theoretical risk as both botulinum toxin and saline have been
demonstrated safe drugs and none of these adverse events have been reported in similar previous
studies.
Benefits
Patients will be offered standard of care physical therapy free of charge during their
participation, which has been demonstrated to improve ITBS symptoms. In addition the
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implementation of botulinum toxin may significantly decrease ITBS symptom severity and
improve physical therapy outcomes.
Economic Considerations
Patients will not be offered compensation for study participation.
Treatment Alternatives
There are no study alternatives. If you do not wish to participate in the study you may
wish to pursue treatment from another provider or continue conservative treatments on your own.
Confidentiality and Privacy
All identifiable data obtained throughout the course of this study will remain confidential
and will only be released with your permission or in accordance with state or federal law. When
the results of this study are published, presented, or shared all data will be deidentified meaning
no information would be related to you or reveal your identity unless permission is granted by
you to do so. Only in cases of abuse to yourself or another, intent to harm yourself or another, or
with certain reportable diseases would your information be mandated by law to be shared with
proper authorities.
By signing this form and enrolling in this study you will allow this research committee to
have access to your medical records including past doctors notes and previous imaging. This is
done to ensure your safety in this study and to ensure you are an eligible candidate. The
information from your medical history will not be shared with any outside party or published.
The research team will deidentify all identifiable data, such as your name or birthdate, and will
code your identity before any data from the study is shared. We will only collect data and
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information relevant to the study protocol and your safety. The data will be stored and collected
on an encrypted HIPPA compliant server.
The Yale Human Research Protection Program and the Yale Human Investigation
Committee will have access to your personal information during the course of the study to ensure
research compliance and participant safety. These individuals are required to maintain
confidentiality.
Voluntary Participation Withdrawal
Participation in this study is completely voluntary and you may withdraw at any time.
You are free to choose to decline this study. Declining this study will not bar you from receiving
medical care that you are entitled to, and will not restrict you from seeking care in any way.
However refusing to participate in this study means you will not receive possible beneficial
treatments.
Withdrawing from the Study
If you do choose to enroll in this study, you are free to stop at any time. There will be no
penalty or consequence of stopping the study. If you start the study and wish to stop, please
simply contact a research team member by phone or email to let us know you no longer wish to
participate. Once you withdraw your permission no new data will be collected. Data already
collected will remain deidentified and will be used throughout the course of the study to maintain
study integrity.
Questions
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Please let us know if there is anything, medical or legal, that you did not understand or
was not explained properly in this form. Our research staff is happy to answer all of your
questions and ensure you are fully informed before you make the decision to participate or not.
Please take the time you need to review this information before making a decision.
Authorization
I have read (or someone has read to me) this form and have decided to continue to
participate in the project described above. Its general purposes, the particulars of involvement
and possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this consent addendum form.
By signing this form, I give permission to the research team to access my medical record,
collect data, and distribute data in accordance with the purposes outlined in this form. By
refusing permission, I understand I will not be able to participate in this study.
I willingly consent to participate in the study-specific blinded tensor fasciae latae
injection.
Initials: ________ Date:__________

Name of Subject:_____________________________
Signature:___________________________________
Date:______________________________________
___________________________________________

___________________

Signature of Person Obtaining Consent

Date
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If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator. If you would like to talk with someone other than the
researchers to discuss problems, concerns, and questions, offer input, discuss situations in the
event that a member of the research team is not available, or if you have any questions
concerning your rights as a research subject, you may contact the Human Investigation
Committee at (203) 785-4688.
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APPENDIX B: Recruitment Flyer

Volunteers Needed for
Research Study
Yale University
We are running a study to see if Botox injections can help reduce knee pain from
chronic iliotibial band syndrome when combined with physical therapy.

Who is Eligible?
·
Ages 18-55
·
Patients who have had iliotibial band syndrome for longer than 6 months,
and have already failed physical therapy
·
Patients who have no other knee conditions or injuries

What will you be asked to do?
·
Receive a one time injection into your hip of either saline or Botox
·
Participate in once weekly physical therapy sessions and in daily at home
physical therapy
·
Come to a total of eight office visits over 6 months

If you are interested or have any questions please contact us at:
·
·

Email: investigator@yale.edu
Phone: (201) XXX-XXX
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APPENDIX C: Sample Size Calculation

Effect Size was calculated with data from Singer et al. 2011 and Stephen et al. 2016.
These numbers were then used to calculate the estimated sample size using Power and Precision
4 Software.

Singer et al. 2011 compared BT injection into the VL to saline injections in the VL
coupled with physical therapy for patellofemoral knee pain. In their treatment group they
reported mean change in knee pain from baseline using the AKPS in individual categories,
reporting a mean change in kneeling 50.5, stair walking 20.9, and squatting 30.8. These numbers
were averaged to give a mean AKPS change in the treatment group of 33.6. The placebo group
demonstrates a mean change in AKPS from baseline of 20.4. The difference in mean change in
AKPS from baseline between the treatment and control group was 13.2. Using this we calculated
the retaliate effect to be 57%.

Stephen et al. 2016 examined the effects of BT injections into the TFL with physical
therapy for ITBS knee pain, but without a control group. They reported a mean AKPS change of
15 points with treatment. Using the relative effect from Singer et al. 2011 of 57% we calculated
an expected effect of an 8.6 point change in the AKPS in the control group. The projected
population mean effect of BT + physical therapy in the TFL for ITBS is a 15 point change in the
AKPS, while the projected mean effect of Control + physical therapy in the TFL for ITBS to be
8.6.
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To increase the likelihood of finding a true statistical significance in our study while
reducing sampling error, and Bonferoni correction was done. This alters our alpha from 0.5% to
1%, therefore increasing our sample size. Power and Precision 4 software was used to calculate
that with a power of 80%, for a 2-tailed T-test and alpha of 1%, we would need 296 subjects to
yield statistical significance and reject the null hypothesis. To account for an expected 10%
attrition rate 330 patients will need to be enrolled.
Figure 1. Sample Size Calculation

Calculated using: Power and Precision. Version 4. Biostat, Inc. Englewood, NJ.
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APPENDIX D: Sample Physical Therapy Log
ITBS Physical Therapy Log
Dear Participant, this is your exercise log for week one. Your Physical Therapist should
review this with you on Day 1, and work through the exercises with you, to make sure you
understand the exercises and how to perform them on your own. Please check off the box
corresponding to the exercise and date as you preform them. You will return this sheet to the
research office at your next appointment and will be given a new exercise log.
Please let the research staff or Physical Therapists know if you have any questions or
concerns.

Week 1

Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7

Standing Legs Criss-cross Arms
Overhead 3x30s
Figure-4 Stretch 3x 30s
Wall Calf Stretch 3x30s
Foam Roll Glutes 2x 30s
Foam Roll Hip Abductors 2x 30s
Foam Roll IT Band 2x30s
Clam Shell 2x10
Side Bridge Hip Dips 2x10
Extended Crunches 2x10
Side Lying Hip Abduction 2x15
Hip Hikes2x10
Single Leg Step Down 2x10
Standing Legs Criss-cross Arms
Overhead 3x30s
***All exercises are to be done on both sides, on your injured leg and your non-injured leg
I (participant name) ____________________________ certify that I have completed the
exercise regime above to the best of my abilities and have recorded my progress accurately.
Participant Signature _______________________________
Date_______________________
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APPENDIX E: Anterior Knee Pain (Kujala) Scale
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Appendix Citations
1. Kujala Scoring Questionnaire. (n.d.). Retrieved 2020, from
https://www.hss.edu/secure/files/WSMC-kujala.pdf
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